Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12447845 | 0.83 | LOXL2 (0.37) | HCAR2 | |
| Hydrochloric Acid SCHEMBL2142116 | 0.81 | LOXL2 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL12802927 | 0.76 | P2RX7 (0.35) | OPRM1OPRL1P2RY14HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL18286214 | 0.76 | VNN1 (0.36) | HCAR2HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL13386459 | 0.75 | KDM1A (0.34) | HSD17B10L3MBTL1P2RY14HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL30454911 | 0.73 | HCAR2 (0.44) | HCAR2HSD17B10C1SITGA4L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL2430505 | 0.72 | KDM4E (0.37) | HCAR2HSD17B10L3MBTL1HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL1670534 | 0.71 | CCR1 (0.38) | L3MBTL1HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL27673223 | 0.70 | HCAR2 (0.41) | HCAR2HSD17B10L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL6386625 | 0.70 | HCAR2 (0.55) | HCAR2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545050-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-13 | — | — | EP | disclosed |
| CN-102906089-A | Compounds for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2013-01-30 | — | — | CN | disclosed |
| EP-2545050-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HCAR2 3492/4885HSD17B10 676/4885OPRM1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.